PL388511A1 - Method for securing solid form of a drug containing 4 - [(4-methylpiperazine-1-yl) methyl]-N-[4-methyl-3-[(4-pyridin-3-ylopirymidyn-2-yl) amino] phenyl] benzamide or its pharmaceutically acceptable forms or variations thereof - Google Patents

Method for securing solid form of a drug containing 4 - [(4-methylpiperazine-1-yl) methyl]-N-[4-methyl-3-[(4-pyridin-3-ylopirymidyn-2-yl) amino] phenyl] benzamide or its pharmaceutically acceptable forms or variations thereof

Info

Publication number: PL388511A1
Authority: PL; Poland
Prior art keywords: methyl; ylopirymidyn; methylpiperazine; benzamide; pyridin
Prior art date: 2009-07-09

Application number

PL388511A

Other languages

Polish (pl)

Other versions

PL231174B1 (en

Inventor

Andrzej Ostrowicz

Original Assignee

Biofarm Spółka Z Ograniczoną Odpowiedzialnością

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-07-09

Filing date

2009-07-09

Publication date

2011-01-17

2009-07-09 Application filed by Biofarm Spółka Z Ograniczoną Odpowiedzialnością filed Critical Biofarm Spółka Z Ograniczoną Odpowiedzialnością

2009-07-09 Priority to PL388511A priority Critical patent/PL231174B1/en

2011-01-17 Publication of PL388511A1 publication Critical patent/PL388511A1/en

2019-01-31 Publication of PL231174B1 publication Critical patent/PL231174B1/en

Links

KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title 2
-1 4-methylpiperazine-1-yl Chemical group 0.000 title 1
239000003814 drug Substances 0.000 title 1
229940079593 drug Drugs 0.000 title 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 title 1
239000007787 solid Substances 0.000 title 1

PL388511A 2009-07-09 2009-07-09 Method for securing solid form of a drug containing 4 - [(4-methylpiperazine-1-yl) methyl]-N-[4-methyl-3-[(4-pyridin-3-ylopirymidyn-2-yl) amino] phenyl] benzamide or its pharmaceutically acceptable forms or variations thereof PL231174B1 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
PL388511A PL231174B1 (en)	2009-07-09	2009-07-09	Method for securing solid form of a drug containing 4 - [(4-methylpiperazine-1-yl) methyl]-N-[4-methyl-3-[(4-pyridin-3-ylopirymidyn-2-yl) amino] phenyl] benzamide or its pharmaceutically acceptable forms or variations thereof

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PL388511A PL231174B1 (en)	2009-07-09	2009-07-09	Method for securing solid form of a drug containing 4 - [(4-methylpiperazine-1-yl) methyl]-N-[4-methyl-3-[(4-pyridin-3-ylopirymidyn-2-yl) amino] phenyl] benzamide or its pharmaceutically acceptable forms or variations thereof

Publications (2)

Publication Number	Publication Date
PL388511A1 true PL388511A1 (en)	2011-01-17
PL231174B1 PL231174B1 (en)	2019-01-31

Family

ID=43502724

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL388511A PL231174B1 (en)	2009-07-09	2009-07-09	Method for securing solid form of a drug containing 4 - [(4-methylpiperazine-1-yl) methyl]-N-[4-methyl-3-[(4-pyridin-3-ylopirymidyn-2-yl) amino] phenyl] benzamide or its pharmaceutically acceptable forms or variations thereof

Country Status (1)

Country	Link
PL (1)	PL231174B1 (en)

2009
- 2009-07-09 PL PL388511A patent/PL231174B1/en unknown

Also Published As

Publication number	Publication date
PL231174B1 (en)	2019-01-31

Similar Documents

Publication	Publication Date	Title
TWI367212B (en)	2012-07-01	Dosage forms of palonosetron hydrochloride having improved stability and bioavailability
ZA201003902B (en)	2011-02-23	Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide
PL2588090T3 (en)	2017-12-29	Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
IL211099A0 (en)	2011-04-28	Formulation for oral administration of proteins
IL230819A0 (en)	2014-03-31	Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist
HUP0600816A2 (en)	2008-05-28	Method of alcohol-induced dose dumping for opioid sustained release oral dosage forms
CL2007002930A1 (en)	2008-04-04	A COMPOUND 4- [4 - ({[4-CHLORINE-3- (TRIFLUOROMETIL) PHENYL] CARBAMOIL} AMINO) -3-FLUOROFENOXI] -N-METHYLPIRIDIN-2-CARBONXAMIDE MONOHIDRATADO; PREPARATION PROCESS; COMPOSITION AND PHARMACEUTICAL COMBINATION; AND USE FOR THE TREATMENT OF HYPERPROLIFERATI DISORDERS
IL211279A (en)	2015-03-31	Use of a tspan12 antagonist in the manufacture of a medicament for inhibiting ocular angiogensis
IL212640A0 (en)	2011-07-31	Process for the preparation of piperazine compounds and hydrochloride salts thereof
IL238477A0 (en)	2015-06-30	Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitor
IL183245A0 (en)	2007-08-19	Process for preparing phamaceutically acceptable salts of duloxetine and intermediates thereof
ZA200903929B (en)	2010-03-31	Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
PL2400954T3 (en)	2017-04-28	Process for forming solid oral dosage forms of solifenacin and its pharmaceutically acceptable salts
EP2456439A4 (en)	2012-12-26	A stable pharmaceutical omeprazole formulation for oral administration
ZA200610770B (en)	2008-08-27	Dosage form for delivery of multiple drug forms
ZA201402756B (en)	2015-04-29	Immediate release 4-methyl-3-[[4-(3-pyridinyl)]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide formulation
IL177402A0 (en)	2006-12-10	Composition for oral administration of tamsulosin hydrochloride
PT2065317E (en)	2015-09-11	Method for storing packets of medicine
MA33883B1 (en)	2013-01-02	The process of formation and crystalline form of hydrochloride 4} 3] c-hexanhydrochlopitan [c] pyrrol-2 (1h)-[yl propoxy {benzamide and the pharmaceutical formulations it contains
PL388511A1 (en)	2011-01-17	Method for securing solid form of a drug containing 4 - [(4-methylpiperazine-1-yl) methyl]-N-[4-methyl-3-[(4-pyridin-3-ylopirymidyn-2-yl) amino] phenyl] benzamide or its pharmaceutically acceptable forms or variations thereof
EP2121729A4 (en)	2013-07-31	Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture
PL394559A1 (en)	2012-10-22	Capsules containing 4-[(4-methylopiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylopyrimidin-2-yl)amine]phenyl]benzamide and process for the preparation thereof
FI7357U1 (en)	2007-01-16	A Method for Reducing Alcohol-Induced Dose Discharge for Long-acting Oral Dosage Forms of Opioids
PL387516A1 (en)	2010-09-27	Pharmaceutical composition containing 4-[(4-metyl piperazine-1-yl)methyl]-N-[4-methyl-3-[(4-pyridine-3-yl pyrimidin-2-yl)amino]phenyl]benzamide, method of its manufacturing and the forms of the medicine containing this composition
PL392269A1 (en)	2012-03-12	Tablet containing 4-[(4-methylopiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylopyrimidin-2-yl)amine]phenyl]benzamide and process for the preparation thereof